Current report No. 2/2024 – Appointment of the President of the Management Board for another term

Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information

Content of the report:

The Management Board of Celon Pharma S.A. (“Company) hereby informs that on 24 January 2024, the Supervisory Board of the Company, acting pursuant to Article 368(4) of the Commercial Companies Code in relation to Article 369(1) and in relation to §17(4)(e) of the Company’s Articles of Association, has adopted a resolution on the appointment – as from the beginning of the day following the Ordinary General Meeting approving the financial statements of the Company for 2023 – of Mr. Maciej Wieczorek, for the position of the President of the Management Board of Celon Pharma S.A., for another 5-year term.

Mr. Maciej Wieczorek is the Company's founder and he has been the President of its Management Board since the beginning of its operations.
Through Glatton sp. z o.o., in which he owns 100% shares, Mr. Maciej Wieczorek is the owner of 58.8% of shares in Celon Pharma S.A., which grant him the right to 68.2% of votes at the General Meeting of the Company.

Mr. Maciej Wieczorek is the creator and co-creator of over a dozen of patent applications concerning classical chemical and biotechnological drugs, as well as the author of implementation of several of the best-selling drugs in Poland.


  • 2008 – title of Doctor of Medicine in the field of medical biology at the Medical University of Lodz;
  • 1997-1999 – management studies under the Warsaw Executive MBA programme, organized jointly by the Warsaw School of Economics and the University of Minnesota (USA).
  • 1990-1991 – International Finance studies at the University of New Lisbon as part of the TEMPUS programme;
  • 1987-1992 – Industrial Organization and Management studies at the Warsaw University of Technology, Faculty of Mechanical and Industrial Engineering. Between 1989 and 1992, an individual course of study, including studies in micro and macroeconomics, law at the Warsaw School of Economics and management at the University of Warsaw.

Professional experience:

  • President of the Management Board of Celon Pharma S.A. since 2002 (until 2012, the Company operated as a limited liability company);
  • President of the Management Board of Mabion S.A. (2007-2016), then Chairman of the Supervisory Board (2017-2020), and Member of the Mabion S.A. Supervisory Board (2020-2021);
  • Managing Director of Adamed sp z o.o., Adamed Pharma S.A. (1994-2002), Vice President of the Management Board, responsible for strategy, research and development and current operations;
  • Credit officer at the Bank Rozwoju Eksportu S.A. in Warsaw (1991-1993) specializing in the financing of industrial projects;
  • Consultant in the chemical and pharmaceutical industry at CDS Concept Sp. z o.o. (1993-1994).

According to the submitted statement, Mr. Maciej Wieczorek does not pursue activities outside the Company that are competitive to the Company's activity, is not a partner in a competitive civil, partnership or capital company, and does not participate in a competitive legal entity as a member of its body. Mr. Maciej Wieczorek is not listed in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.